MannKind Corp

MNKD

Market cap $1.71B

MoneyShow presents top investment ideas for 2026 from their contributors. This year's edition presents a mix of metals plays, financial stocks, deep value names, high-octane growth and tech stocks, and beaten-down REITs that offer solid income and turnaround potential. Part 5 of this series includes Hormel Foods, IonQ, Kodiak AI, Lara Exploration and MannKind.

MannKind (MNKD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Top stock-market newsletter editors share gems from their ‘buy' list.

DANBURY, Conn. and WESTLAKE VILLAGE, Calif.

On Dec. 17, 2025, Michael Castagna, Chief Executive Officer of MannKind Corporation (MNKD +0.00%), executed an exercise and immediate sale of 65,804 common shares for a transaction value of approximately $395,482, according to the SEC Form 4 filing.

FDA approves FUROSCIX ® for use in pediatric patients weighing 43kg or above USPTO issues five patents for FUROSCIX ReadyFlow ™ Autoinjector WESTLAKE VILLAGE, Calif. and BURLINGTON, Mass.

MannKind Corporation delivered strong Q3 '25 results, beating EPS and revenue estimates, and shares have responded positively. The FDA accepted the supplemental New Drug Application for the FUROSCIX ReadyFlow Autoinjector, offering rapid furosemide delivery for CHF and CKD patients. I see a substantial TAM, estimating 670,000 to 1.34 million potential U.S. heart failure patients for ReadyFlow, with significant revenue implications.

If approved, ReadyFlow Autoinjector would deliver an IV-equivalent diuretic dose (subcutaneous furosemide injection 80 mg/ml) in under 10 seconds Would potentially provide a cost-effective and convenient option to address episodes of fluid buildup at home, benefiting patients, providers and payors PDUFA target action date of July 26, 2026 WESTLAKE VILLAGE, Calif. and BURLINGTON, Mass.

DANBURY, Conn. and WESTLAKE VILLAGE, Calif.

MannKind Corporation ( MNKD ) Discusses Discontinuation of ICoN-1 Phase III Trial for Nebulized Clofazimine in NTM Lung Disease November 10, 2025 9:00 AM EST Company Participants Michael Castagna - CEO & Director Conference Call Participants Olivia Brayer - Cantor Fitzgerald & Co., Research Division Benjamin Burnett - Wells Fargo Securities, LLC, Research Division Faisal Khurshid - Leerink Partners LLC, Research Division Brandon Folkes - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good morning, and welcome to MannKind Corporation's investor call to discuss a clinical trial update.